Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10016


Purpose:

The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.


Criteria:

Inclusion Criteria: - Confirmed relapsed ovarian cancer. - Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan). - One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin. - At least three weeks since prior chemotherapy and recovery from any related toxicities. - At least four weeks since prior radiotherapy and recovery from any related toxicities.


NCT ID:

NCT00046800


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

New York, New York 10016
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.